Abstract: Derivatives of 10S, 17S-diHIDA (protectin DX, PDX) and medicinal uses thereof are disclosed. These derivatives are specialized pro-resolving mediators (SPRMs). In specific embodiments, said derivatives are used in to prevent or treat viral infections (including influenza and coronavirus infections), insulin resistance, diabetes, and inflammatory disorders.

Abstract: Novel chemical agents are described herein. More specifically, a novel inhibitor of 17?-HSD7 for decreasing estradiol concentrations while restoring dihydrotestosterone (DHT) concentrations in breast cancer cells is disclosed herein. In a particular embodiment, the inhibitor of 17?-HSD7 has the following structure: (Formula I) A process for producing the novel inhibitors of 17?-HSD7 and their use in the manufacture of pharmaceutical formulations and/or combinations is also disclosed.

Abstract: A method for the synthesis of specialized pro-resolving mediators, structural isomers thereof and analogs thereof is disclosed herein. The method comprises reacting a compound of the formula (I): wherein R1 is alkyl(C?12), cycloalkyl(C?12), alkenyl(C?12), alkylidene(C?12), alkynyl(C?12), aryl, aralkyl, heteroaryl or heteroaralkyl; and X1, X2 and X3 are each independently hydroxy or OP, wherein P is a hydroxy protecting or hydroxy activating group; with a reducing agent under conditions sufficient to produce a compound of the formula (II): wherein: R1, X1, X2 and X3 are as defined above. Novel protectins, more specifically novel structural isomers and analogs of PD1 and PDX are also disclosed.

Abstract: A multi-path cleaning system is provided for a fuel tank. The multi-path cleaning system includes a controller, a fuel polisher, and a plurality of controllable valves. The plurality of controllable valves are operatively connected to the controller, and each valve fluidly coupled to at least one of the inlet and outlet of the fuel polisher on a first side and the interior of the fuel tank on a second other side. The pump, when operated, causes fuel to be drawn through the inlet and discharged at the outlet of the fuel polisher, and to pass through at least one filter/water separator. Selective operation of the plurality of valves by the controller selectively fluidly couples portions of the interior of the fuel tank to the inlet and the outlet of the fuel polisher, thereby creating a plurality of fluid flow paths through the interior of the fuel tank.

Abstract: A fuel system for a generating unit disposed within an enclosure, the enclosure having an enclosure width and an enclosure height, includes a bulk fuel storage tank and a vertical day tank, a supply line and a return line. The vertical day tank has a tank width corresponding to the enclosure width, a tank height corresponding to the enclosure height, and a tank depth selected to provide an interior volume to meet fuel capacity requirements for the generating unit. The tank height and tank width both exceed the tank depth. The vertical day tank further has a fill port and an overfill port located at a top of the vertical day tank. The supply line runs from the bulk fuel tank to the fill port of the vertical day tank, and the return line runs from the overfill port of the vertical day tank to the bulk fuel storage tank.

Abstract: Estrane-based and androstane-based aminosteroid derivatives are described herein. More specifically, the following piperazinyl-steroid compounds of Formula I, Formula II, Formula III, and Formula IV are described. The compounds display cytotoxicity on a variety of cancer cell lines. A process for producing the compounds and their use in the manufacture of pharmaceutical formulations and/or combinations is also disclosed.

Abstract: The present application discloses 17? hydroxy steroid dehydrogenase (17? HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17? HSD1 inhibitors include estradiol derivatives with a nieta-carbamoylbenzyl substituent at C 16. 17? HSD3/HSD10 inhibitors include androsterone derivatives substituted at the C3 position with a sulfonamide piperazine. Also disclosed are compounds that are inhibitors of both 17? HSD1 and 17? HSD3 that have a spiro-morpholine substituent at C20.

Abstract: A multi-path cleaning system is provided for a fuel tank. The multi-path cleaning system includes a controller, a fuel polisher, and a plurality of controllable valves. The plurality of controllable valves are operatively connected to the controller, and each valve fluidly coupled to at least one of the inlet and outlet of the fuel polisher on a first side and the interior of the fuel tank on a second other side. The pump, when operated, causes fuel to be drawn through the inlet and discharged at the outlet of the fuel polisher, and to pass through at least one filter/water separator. Selective operation of the plurality of valves by the controller selectively fluidly couples portions of the interior of the fuel tank to the inlet and the outlet of the fuel polisher, thereby creating a plurality of fluid flow paths through the interior of the fuel tank.

Abstract: A multi-path cleaning system is provided for a fuel tank. The multi-path cleaning system includes a controller, a fuel polisher, and a plurality of controllable valves. The plurality of controllable valves are operatively connected to the controller, and each valve fluidly coupled to at least one of the inlet and outlet of the fuel polisher on a first side and the interior of the fuel tank on a second other side. The pump, when operated, causes fuel to be drawn through the inlet and discharged at the outlet of the fuel polisher, and to pass through at least one filter/water separator. Selective operation of the plurality of valves by the controller selectively fluidly couples portions of the interior of the fuel tank to the inlet and the outlet of the fuel polisher, thereby creating a plurality of fluid flow paths through the interior of the fuel tank.

Abstract: Estrane-based and androstane-based aminosteroid derivatives are described herein. More specifically, the following piperazinyl-steroid compounds of Formula I, Formula II, Formula III, and Formula IV are described. The compounds display cytotoxicity on a variety of cancer cell lines. A process for producing the compounds and their use in the manufacture of pharmaceutical formulations and/or combinations is also disclosed.

Abstract: A fluid filter system has at least one filter having a filter head removable filter element, the filter being oriented inverted. A first filter drain check valve is provided with its inlet in fluid communication with the inlet of the at least one filter, and a second filter drain check valve is provided with its inlet in fluid communication with the outlet of the at least one filter. A filter outlet check valve is provided with its inlet in fluid communication with the outlet of at least one filter head. An openable valve is provided in fluid communication with the outlets of the first and second filter drain check valves. A drain pump is provided with its intake in fluid communication with the valve. A drain pump check valve is included with its inlet in fluid communication with the output of the drain pump and an outlet in fluid communication with the outlet of the filter outlet check valve.

Abstract: A multi-path cleaning system is provided for a fuel tank. The multi-path cleaning system includes a controller, a fuel polisher, and a plurality of controllable valves. The plurality of controllable valves are operatively connected to the controller, and each valve fluidly coupled to at least one of the inlet and outlet of the fuel polisher on a first side and the interior of the fuel tank on a second other side. The pump, when operated, causes fuel to be drawn through the inlet and discharged at the outlet of the fuel polisher, and to pass through at least one filter/water separator. Selective operation of the plurality of valves by the controller selectively fluidly couples portions of the interior of the fuel tank to the inlet and the outlet of the fuel polisher, thereby creating a plurality of fluid flow paths through the interior of the fuel tank.

Abstract: A fluid filter system has at least one filter having a filter head removable filter element, the filter being oriented inverted. A first filter drain check valve is provided with its inlet in fluid communication with the inlet of the at least one filter, and a second filter drain check valve is provided with its inlet in fluid communication with the outlet of the at least one filter. A filter outlet check valve is provided with its inlet in fluid communication with the outlet of at least one filter head. An openable valve is provided in fluid communication with the outlets of the first and second filter drain check valves. A drain pump is provided with its intake in fluid communication with the valve. A drain pump check valve is included with its inlet in fluid communication with the output of the drain pump and an outlet in fluid communication with the outlet of the filter outlet check valve.

Abstract: Provided are compounds of general formula A and A?, wherein X1 and X2 are each C, CH or N; R3 and R4 are each H, optionally substituted C1-C30 saturated or unsaturated chemical group, or together form an optionally substituted C5-C8 cycle; Z1; Z2 and Z3 are each N or CH; V is C?O, C?S or CH2; n is from 1 to 12; W1 and W2 are each H, CH2, O or S; and R1 and R2 are each H, Cr1C6 alkyl, C1C6 aryl, C1C12 alkylaryl, optionally substituted phenyl, C1C6 alkoxy, C1C6 thioalkoxy, F, Cl, Br or I. These compounds inhibit steroid sulfatase (STS), act as selective estrogen receptor modulators (SERMs), increase alkaline phosphatase (ALP) activity, and are useful in the treatment of medical conditions involving hormones such as breast cancer, prostate cancer, endometriosis, osteoporosis, benign prostatic hyperplasia and endometrial cancer.

Abstract: Provided are compounds of general formula A and A?, wherein X1 and X2 are each C, CH or N; R3 and R4 are each H, optionally substituted C1-C30 saturated or unsaturated chemical group, or together form an optionally substituted C5-C8 cycle; Z1; Z2 and Z3 are each N or CH; V is C?O, C?S or CH2; n is from 1 to 12; W1 and W2 are each H, CH2, O or S; and R1 and R2 are each H, Cr1C6 alkyl, C1C6 aryl, C1C12 alkylaryl, optionally substituted phenyl, C1C6 alkoxy, C1C6 thioalkoxy, F, Cl, Br or I. These compounds inhibit steroid sulfatase (STS), act as selective estrogen receptor modulators (SERMs), increase alkaline phosphatase (ALP) activity, and are useful in the treatment of medical conditions involving hormones such as breast cancer, prostate cancer, endometriosis, osteoporosis, benign prostatic hyperplasia and endometrial cancer.

Abstract: The present application discloses 17? hydroxy steroid dehydrogenase (17? HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17? HSD1 inhibitors include estradiol derivatives with a nieta-carbamoylbenzyl substituent at C 16. 17? HSD3/HSD10 inhibitors include androsterone derivatives substituted at the C3 position with a sulfonamide piperazine. Also disclosed are compounds that are inhibitors of both 17? HSD1 and 17? HSD3 that have a spiro-morpholine substituent at C20.

Abstract: Novel chemical agents are described herein. More specifically, 2-(N-substituted piperazinyl) pregnane and 2-(N-substituted piperazinyl) androstane derivatives exhibiting cytotoxicity on a variety of cancer cell lines are disclosed herein.

Abstract: Novel chemical agents are described herein. More specifically, 2-(N-substituted piperazinyl) pregnane and 2-(N-substituted piperazinyl) androstane derivatives exhibiting cytotoxicity on a variety of cancer cell lines are disclosed herein.

Abstract: Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17&bgr;-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17&bgr;-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase.

Abstract: Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17&bgr;-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17&bgr;-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase.